Wall Street analysts’ outlook for Deciphera Pharmaceuticals Inc. (DCPH)

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock fell -1.55% on Friday to $18.40 against a previous-day closing price of $18.69. With 3.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.63 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $20.15 whereas the lowest price it dropped to was $18.17. The 52-week range on DCPH shows that it touched its highest point at $22.76 and its lowest point at $6.51 during that stretch. It currently has a 1-year price target of $21.22. Beta for the stock currently stands at 0.71.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DCPH was down-trending over the past week, with a drop of -16.74%, but this was up by 23.91% over a month. Three-month performance surged to 10.71% while six-month performance rose 36.09%. The stock gained 116.98% in the past year, while it has gained 12.26% so far this year. A look at the trailing 12-month EPS for DCPH yields -3.46 with Next year EPS estimates of -2.28. For the next quarter, that number is -0.57. This implies an EPS growth rate of -8.10% for this year and 8.10% for next year. EPS is expected to grow by 21.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -43.60%.

Float and Shares Shorts:

At present, 78.21 million DCPH shares are outstanding with a float of 49.05 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.38 million, which was 11.05% higher than short shares on Sep 14, 2022. In addition to Mr. Steven L. Hoerter as the firm’s Pres, CEO & Director, Dr. Daniel L. Flynn Ph.D. serves as its Exec. VP, Chief Scientific Officer & Founder.


Institutional Ownership:

Through their ownership of 74.37% of DCPH’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 46.19% of DCPH, in contrast to 33.16% held by mutual funds. Shares owned by individuals account for 24.92%. As the largest shareholder in DCPH with 7.06% of the stake, Armistice Capital LLC holds 4,768,000 shares worth 4,768,000. A second-largest stockholder of DCPH, The Vanguard Group, Inc., holds 4,719,230 shares, controlling over 6.98% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in DCPH, holding 3,728,006 shares or 5.52% stake. With a 3.67% stake in DCPH, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,479,181 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.13% of DCPH stock, is the second-largest Mutual Fund holder. It holds 1,439,564 shares valued at 23.59 million. Polar Capital Funds Plc – Biotech holds 1.85% of the stake in DCPH, owning 1,250,000 shares worth 20.49 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DCPH since 11 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DCPH analysts setting a high price target of $28.00 and a low target of $9.00, the average target price over the next 12 months is $20.09. Based on these targets, DCPH could surge 52.17% to reach the target high and fall by -51.09% to reach the target low. Reaching the average price target will result in a growth of 9.18% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DCPH will report FY 2022 earnings on 02/07/2024. Analysts have provided yearly estimates in a range of -$2.43 being high and -$2.65 being low. For DCPH, this leads to a yearly average estimate of -$2.48. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Deciphera Pharmaceuticals Inc. surprised analysts by $0.03 when it reported -$0.55 EPS against a consensus estimate of -$0.58. The surprise factor in the prior quarter was $0.06. Based on analyst estimates, the high estimate for the next quarter is -$0.52 and the low estimate is -$0.70. The average estimate for the next quarter is thus -$0.57.

Summary of Insider Activity:

Insiders traded DCPH stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 1,478,978 while 19,660 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *